Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.7%

1 terminated out of 15 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

90% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (6)
P 3 (1)
P 4 (1)

Trial Status

Completed9
Recruiting3
Unknown2
Terminated1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05704881Recruiting

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

NCT04955080Completed

REal-time Data Monitoring for Shared Adaptive, Multi-domain and Personalised Prediction and Decision Making for Long-term Pulmonary Care Ecosystems (RE-SAMPLE)

NCT07065799Not ApplicableRecruiting

Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation

NCT03033251Not ApplicableRecruitingPrimary

High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease

NCT06801964Not ApplicableCompleted

AECOPD and Nutritional Supplementation in COPD

NCT05779384Completed

The COPD Attack Study

NCT05750810Completed

Exacerbations and Their Outcomes International (EXACOS International)

NCT04802096Not ApplicableCompletedPrimary

Effects of Inspiratory Muscle Training in Addition to Pulmonary Rehabilitation in Patients With COPD Exacerbation

NCT05380869Not ApplicableCompleted

POCT PCT in Outpatient LRTI

NCT03153826Not ApplicableTerminated

Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of COPD

NCT04319705Phase 4Unknown

Anti-viral Effects of Azithromycin in Patients With Asthma and COPD

NCT02972775Completed

15-year Mortality After Hospitalization for Exacerbation of Chronic Obstructive Pulmonary Disease

NCT03432234Unknown

Respiratory Microbiome and COPD Exacerbations (RESMECOPD)

NCT04122547Phase 3CompletedPrimary

Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis

NCT03256604Completed

A Sputum Screening Test to Rule-out Pneumonia at an Early Stage

Showing all 15 trials

Research Network

Activity Timeline